Affiniti Series Diagnostic Ultrasound Systems vs EchoNext
AI Verdict
Choose Affiniti Series Diagnostic Ultrasound Systems if…
Choose Philips Affiniti Series Diagnostic Ultrasound Systems if your practice requires a versatile, mid-tier ultrasound solution for comprehensive diagnostic imaging across cardiology, OB/GYN, and radiology. Its advanced features like PureWave technology and Anatomical Intelligence are ideal for achieving high-quality images and efficient workflows, especially when detailed anatomical visualization and reproducible results are crucial for confident diagnoses.
View Affiniti Series Diagnostic Ultrasound Systems →Choose EchoNext if…
Choose EchoNext if your primary goal is early, non-invasive screening for hidden structural heart disease using standard ECGs, particularly in a broad patient population. This FDA-cleared AI tool is well-suited for identifying patients at risk for conditions like heart failure, valve disease, and pulmonary hypertension, thereby guiding decisions for further cardiac ultrasound (echocardiogram) and enabling earlier intervention.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Affiniti Series Diagnostic Ultrasound Systems | EchoNext |
|---|---|---|
| Pricing | Varies by model and condition (new/refurbished). generally considered a 'mid tier' or 'budget' shared service ultrasound with rich image quality at an affordable price point compared to premium models. | Starts at $600/month |
| Deployment | On-premise (console hardware system) | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Affiniti Series Diagnostic Ultrasound SystemsPhilips Affiniti Series is designed for 'walk-up usability' with an intuitive, tablet-like touchscreen interface that reduces button pushes and training time for new staff. This focus on ergonomic design and streamlined workflow directly addresses common pain points for ultrasound clinicians.
Clinical Value
EchoNextEchoNext offers a novel approach by detecting hidden structural heart disease from standard ECGs, a widely available and inexpensive test. This has the potential to significantly improve early detection and guide further diagnostic steps, outperforming cardiologists in some studies.
Pricing & Value
EchoNextEchoNext's subscription-based pricing model, starting at $600/month, offers clear, tiered options and an annual discount, providing transparency and scalability for different organizational sizes. In contrast, the Philips Affiniti Series, while offering 'affordable' options, has a wider and less transparent price range that varies significantly by model and condition.
Enterprise Readiness
EchoNextEchoNext is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, indicating a strong existing infrastructure for broad deployment and integration into clinical workflows. Its cloud-based nature also offers inherent scalability. Philips Affiniti Series, while a robust on-premise system, requires hardware deployment and integration into existing imaging departments.
Innovation
EchoNextEchoNext represents a significant innovation by leveraging AI to extract diagnostic information about structural heart disease from routine ECGs, a capability traditionally not associated with ECGs. This redefines the utility of a common, inexpensive test. While Philips Affiniti Series incorporates advanced imaging technologies and AI for workflow optimization, it builds upon existing ultrasound diagnostic paradigms.
Support & Docs
TieBoth companies are established in the healthcare space and are expected to offer comprehensive support and documentation. Philips, as a large medical device manufacturer, has extensive service networks and documentation for its hardware systems. Pathway Labs, with its collaboration with OpenEvidence and ongoing research, would also need robust support for its AI tool, including a publicly released dataset and model weights for transparency and further research.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Affiniti Series Diagnostic Ultrasound Systems | EchoNext |
|---|---|---|
| Name | Affiniti Series Diagnostic Ultrasound Systems | EchoNext |
| Company | Philips Ultrasound | Pathway Labs |
| Description | The Philips Affiniti Series Diagnostic Ultrasound Systems offer advanced imaging for diverse clinical needs, featuring PureWave technology, Anatomical Intelligence, and efficient workflows for confident diagnosis. | EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features | PureWave crystal technology, Tissue Specific Presets (TSPs), Anatomical Intelligence Ultrasound (AIUS), xMatrix transducer technology, NextGen Auto Scan, TrueVue and FlexVue, Flow Viewer and MicroFlow Imaging (MFI), ShearWave and Strain elastography | AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support |
| Specialties | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Affiniti Series Diagnostic Ultrasound Systems and EchoNext.